Diagnosis of Anovulation: A Complete Guide to Unpredictable Ovulation, Spotting, and the Tests That Explain Both

Anovulation is the absence of ovulation, the monthly release of a mature egg from the ovary, during a menstrual cycle. Without ovulation, fertilisation cannot occur, making anovulation one of the leading causes of female infertility. According to a 2026 commentary in Human Reproduction, ovulatory disorders contribute to up to 40% of infertility cases, and a history of amenorrhea (absent periods) or oligomenorrhea (infrequent periods) is itself sufficient to suspect ovulatory dysfunction.

Anovulation is not always obvious. Some women with anovulation still experience monthly bleeding, but that bleeding is not preceded by ovulation. The spectrum of ovulatory disorders also includes intermittent anovulation, where ovulation occurs in some cycles but not others, and luteinized unruptured follicle syndrome, where a follicle develops but never releases its egg. This is why a careful clinical assessment, rather than period tracking alone, is essential for an accurate diagnosis of anovulation.

Understanding anovulation matters because it is, in most cases, a treatable condition. Once the underlying hormonal or structural cause is identified, targeted treatment, from lifestyle changes to ovulation induction medications, can restore ovulatory function and significantly improve the chances of conception.

The most reliable sign of anovulation is a disruption in the normal menstrual pattern. According to a 2015 paper in Fertility and Sterility, ovulatory disorders typically manifest as abnormalities in menstrual bleeding frequency, regularity, duration, or volume, ranging from complete absence of periods (amenorrhea) to infrequent cycles longer than 35 days (oligomenorrhea) and abnormal uterine bleeding.

Beyond menstrual irregularity, women with anovulation may notice the absence of mid-cycle signs that normally accompany ovulation: no change in cervical mucus to a clear, stretchy consistency, no brief one-sided pelvic pain (mittelschmerz), and no rise in basal body temperature in the second half of the cycle. Home urinary LH surge kits may show no detectable LH peak, or an LH peak that does not lead to a temperature rise.

Other physical symptoms depend on the underlying cause. Women with polycystic ovary syndrome (PCOS), the most common cause of anovulation, may also experience acne, excess facial or body hair (hirsutism), and weight gain. Women with hyperprolactinemia (elevated prolactin) may notice milky nipple discharge (galactorrhoea). Thyroid dysfunction can present with fatigue, weight changes, or feeling unusually cold or warm. Recognising these associated symptoms helps guide which hormonal tests to prioritise. Acne in pregnancy and while trying is covered in acne treatment in pregnancy.

• Cycles shorter than 21 days or longer than 35 days
• Complete absence of periods for three or more months
• Irregular, unpredictable cycle lengths varying by more than seven days
• Premenstrual spotting or very light, short periods
• No detectable LH surge on home ovulation predictor kits
• Absence of mid-cycle cervical mucus changes or basal body temperature rise
• Milky nipple discharge, acne, hirsutism, or unexplained weight changes

Anovulation is caused by disruptions to the hormonal signals that govern the menstrual cycle. According to a review in the Journal of Clinical Pathology, the principal causes include polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, hyperprolactinemia, thyroid disorders, and premature ovarian insufficiency (POI). Each of these conditions interferes with the hypothalamic-pituitary-ovarian axis at a different point, which is why identifying the specific cause is essential before starting treatment.

Polycystic ovary syndrome (PCOS) is the single most common cause of anovulatory infertility. In PCOS, elevated LH and insulin levels disrupt follicle development, preventing any one follicle from maturing fully and triggering ovulation. Women with PCOS often have multiple small follicles visible on ultrasound, the characteristic 'necklace' appearance, alongside irregular cycles and elevated androgens. Learning more about PCOS and its impact on fertility can help women understand their diagnosis and treatment options.

Hypothalamic amenorrhea occurs when the hypothalamus reduces its output of GnRH (gonadotropin-releasing hormone) in response to physical or psychological stress, significant weight loss, or excessive exercise. This suppresses FSH and LH, halting follicle development entirely. Hyperprolactinemia (elevated levels of the hormone prolactin, often caused by a small benign pituitary tumour called a prolactinoma) similarly suppresses GnRH pulsatility and inhibits ovulation. Thyroid disorders, both hypothyroidism and hyperthyroidism, alter the hormonal environment in ways that disrupt the menstrual cycle and impair ovulation. Premature ovarian insufficiency (POI) refers to the depletion or dysfunction of ovarian follicles before the age of 40, leading to elevated FSH and low oestrogen levels.

• Cause: PCOS · Key Hormonal Pattern: Elevated LH, elevated androgens, normal or low FSH · Associated Symptoms: Irregular cycles, hirsutism, acne, weight gain
• Cause: Hypothalamic amenorrhea · Key Hormonal Pattern: Low FSH, low LH, low oestrogen · Associated Symptoms: Absent periods, low body weight, intense exercise history
• Cause: Hyperprolactinemia · Key Hormonal Pattern: Elevated prolactin, suppressed LH/FSH · Associated Symptoms: Milky nipple discharge, headaches, visual changes
• Cause: Thyroid disorder · Key Hormonal Pattern: Abnormal TSH, T3 or T4 · Associated Symptoms: Fatigue, weight changes, temperature sensitivity
• Cause: Premature ovarian insufficiency · Key Hormonal Pattern: Elevated FSH (>25 IU/L), low AMH, low oestrogen · Associated Symptoms: Hot flushes, absent periods, low ovarian reserve

The diagnosis of anovulation is established through a combination of menstrual history, targeted blood tests, and pelvic ultrasound. The cornerstone confirmatory test is a mid-luteal serum progesterone measurement, taken approximately seven days before the expected next period (around day 21 in a 28-day cycle). According to a 2019 review in the Journal of Clinical Pathology, a luteal-phase progesterone above 30 nmol/L confirms that ovulation has occurred. A lower result is not conclusive on its own, because the timing of the blood draw matters, so your doctor will read it together with your cycle history.

Alongside progesterone, a panel of serum hormone assays is drawn, typically on days 2–4 of the menstrual cycle. This panel includes FSH (follicle-stimulating hormone), LH (luteinising hormone), oestradiol, prolactin, and thyroid function tests (TSH, free T4). Elevated FSH with low oestradiol suggests diminished ovarian reserve or POI; a raised LH-to-FSH ratio with elevated androgens points toward PCOS; elevated prolactin identifies hyperprolactinemia; and abnormal TSH flags thyroid disease as the underlying driver.

Pelvic ultrasound, ideally transvaginal, completes the initial assessment. It allows the clinician to visualise ovarian morphology (including the polycystic appearance of PCOS), measure the antral follicle count (AFC), track follicular growth across the cycle, and identify structural abnormalities of the uterus or ovaries. Serial ultrasound scans across a cycle can directly confirm whether a dominant follicle develops and ruptures, providing real-time evidence of ovulation or its absence. Ovarian reserve testing (which combines AMH, AFC, and day 2–4 FSH) is often incorporated at this stage to give a fuller picture of ovarian function.

The diagnosis of anovulation is rarely the end of the investigation. A complete fertility workup evaluates every factor that could prevent conception, including ovarian reserve, tubal patency, uterine anatomy, and sperm quality. According to an Australian Family Physician review, this evaluation should include serum AMH (anti-Müllerian hormone), antral follicle count, day 2–4 FSH and oestradiol, tubal patency testing, uterine cavity assessment, and semen analysis performed to WHO reference criteria.

Ovarian reserve testing centres on AMH, a hormone produced by small antral follicles that reflects the remaining egg pool. AMH can be measured on any day of the cycle and does not fluctuate significantly between cycles, making it a practical and reliable marker. A low AMH does not mean conception is impossible (it indicates the size of the remaining pool, not egg quality) but it does influence treatment planning, particularly for women considering IVF or egg freezing.

Tubal patency tests assess whether the fallopian tubes are open and functional. Hysterosalpingography (HSG) uses a contrast dye and X-ray to outline the uterine cavity and tubes; hysterosalpingo-contrast sonography (HyCoSy) achieves the same using ultrasound and a saline or foam contrast agent, avoiding radiation. Both tests can detect blockages, adhesions, or hydrosalpinx (fluid-filled tubes). Uterine cavity evaluation is performed with 3D ultrasound as a first-line tool; if abnormalities such as polyps, fibroids, or a septum are suspected, saline infusion sonography (SIS) or diagnostic hysteroscopy provides definitive assessment. Semen analysis must always be part of the workup, as male-factor infertility contributes to roughly half of all infertility cases. Where semen analysis reveals abnormalities, further tests such as sperm DNA fragmentation testing may be recommended.

• Test: Mid-luteal serum progesterone · What It Assesses: Confirms ovulation occurred (>30 nmol/L) · Timing / Notes: Day 21 of a 28-day cycle, or 7 days before next period
• Test: FSH, LH, oestradiol · What It Assesses: Pituitary-ovarian axis function · Timing / Notes: Days 2–4 of cycle
• Test: AMH (anti-Müllerian hormone) · What It Assesses: Ovarian reserve, size of remaining egg pool · Timing / Notes: Any day of cycle
• Test: Antral follicle count (AFC) · What It Assesses: Ovarian reserve, number of small follicles visible · Timing / Notes: Transvaginal ultrasound, days 2–5
• Test: Prolactin · What It Assesses: Rules out hyperprolactinemia · Timing / Notes: Any day; avoid stress before draw
• Test: TSH / thyroid function · What It Assesses: Rules out thyroid-driven anovulation · Timing / Notes: Any day of cycle
• Test: HSG or HyCoSy · What It Assesses: Tubal patency and uterine outline · Timing / Notes: Days 7–10 of cycle, after period ends
• Test: 3D ultrasound / SIS / hysteroscopy · What It Assesses: Uterine cavity, polyps, fibroids, septum · Timing / Notes: As indicated by initial scan findings
• Test: Semen analysis · What It Assesses: Sperm count, motility, morphology (WHO criteria) · Timing / Notes: After 2–5 days abstinence

Distinguishing anovulation from other infertility causes requires a systematic exclusion process. According to the 2023 ESHRE guideline on unexplained infertility, unexplained infertility, a diagnosis that affects a significant proportion of couples, can only be assigned after ovulatory dysfunction, tubal disease, uterine abnormalities, and male-factor causes have all been formally ruled out. Anovulation is identified by menstrual irregularity and a confirmatory low mid-luteal progesterone; if progesterone is normal and cycles are regular, the investigation shifts to structural and male-factor causes.

Dysfunctional uterine bleeding (DUB) can mimic anovulation because it also produces irregular or heavy bleeding. However, DUB is a diagnosis of exclusion, structural causes (polyps, fibroids, adenomyosis) and systemic causes (coagulation disorders, thyroid disease) must be ruled out first. In anovulatory cycles, the endometrium is exposed to unopposed oestrogen without the stabilising effect of progesterone, which can cause irregular, sometimes heavy, breakthrough bleeding. Confirming low progesterone in the mid-luteal phase distinguishes this from structural DUB.

Women with unexplained infertility have regular ovulatory cycles, normal tubes, a normal uterine cavity, and a normal semen analysis, yet conception does not occur. This is a fundamentally different clinical picture from anovulation, and the treatment pathways diverge accordingly. Similarly, endometriosis and recurrent miscarriage each require their own diagnostic workup and should not be conflated with anovulatory infertility, even when cycle irregularity is present.

Treatment following the diagnosis of anovulation is directed at the underlying cause. According to a review in the Journal of Clinical Pathology (2019), the treatment ladder moves from lifestyle modification through hormone therapies to ovulation induction medications and, where necessary, assisted reproductive technologies including IVF and ICSI.

Lifestyle modification is the first-line intervention for hypothalamic amenorrhea and PCOS-related anovulation. In hypothalamic amenorrhea, restoring a healthy body weight, reducing exercise intensity, and addressing psychological stress can resume spontaneous ovulation without any medication. In PCOS, even a 5–10% reduction in body weight in women who are overweight can restore ovulatory cycles. Hormone therapies target specific hormonal deficiencies: dopamine agonists (bromocriptine or cabergoline) normalise prolactin levels in hyperprolactinemia; levothyroxine corrects hypothyroidism; and oestrogen-progesterone support may be used in POI.

Ovulation induction is the mainstay of medical treatment for anovulatory infertility. Letrozole (an aromatase inhibitor) is now preferred over clomiphene citrate for women with PCOS, given its higher live birth rates and lower multiple pregnancy risk. Gonadotropin injections (FSH with or without LH) are used when oral agents fail, requiring careful ultrasound monitoring to reduce the risk of ovarian hyperstimulation syndrome (OHSS). When ovulation induction alone is insufficient (or when tubal, uterine, or male-factor issues coexist) IUI (intrauterine insemination) or IVF may be recommended. For cases involving severe male-factor infertility alongside anovulation, ICSI or PICSI can be combined with ovulation induction as part of an IVF cycle. Where ovarian reserve is critically low, donor egg IVF may offer the best path to pregnancy, conducted in full compliance with the ART (Regulation) Act 2021.

Jananam Fertility Centre is a single-speciality fertility clinic in Neelankarai, Chennai, focused exclusively on the investigation and treatment of infertility. Because the clinic treats only fertility cases, every diagnostic protocol, from the initial hormone panel to serial follicle tracking ultrasounds, is designed around reproductive medicine rather than general gynaecology. The team's consultants bring over two decades of combined experience in reproductive medicine, and the diagnostic workup for anovulation is tailored to each woman's hormonal profile, cycle history, and reproductive goals.

The clinic's Certified Cleanroom Laboratory is particularly relevant for women whose diagnosis of anovulation is accompanied by low ovarian reserve or poor ovarian response. In these cases, the quality of the laboratory environment directly affects embryo development outcomes. A cleanroom lab maintains tightly controlled air quality, temperature, humidity, and pH, conditions that matter most when the number of eggs retrieved is small and every embryo counts. Ovarian reserve testing at Jananam includes AMH, antral follicle count, and day 2–4 FSH, interpreted in the context of the full clinical picture rather than as isolated numbers.

Chennai's urban population faces fertility challenges common to many Indian cities: delayed marriage and childbearing, high rates of PCOS driven partly by dietary and lifestyle factors, and environmental stressors that can contribute to hypothalamic suppression. The team at Jananam is experienced in navigating these patterns and in providing a diagnostic pathway that is thorough, efficient, and sensitive to the emotional weight that an infertility investigation carries. Fertility treatment outcomes vary by age, diagnosis, and individual response to treatment, and your consultant will discuss realistic expectations at every stage. Learn more about the clinic's approach.

A fertility specialist should be consulted whenever anovulation is suspected or confirmed, or when menstrual irregularities persist despite initial management by a general practitioner. According to Fertility and Sterility (2015), specialist referral is warranted earlier in women over 35, in those with a known risk factor for ovulatory dysfunction (such as a history of absent or infrequent periods), and in any woman who has been trying to conceive for 12 months without success, or six months if she is over 35.

Specialist evaluation goes beyond confirming the diagnosis of anovulation. It includes a detailed endocrine assessment to identify the precise hormonal driver, a structural assessment of the uterus and tubes, and a semen analysis for the partner. This comprehensive picture allows the team to recommend the most appropriate treatment pathway from the outset, rather than working through a series of empirical treatments without a clear diagnosis.

It is worth seeking specialist advice sooner rather than later if you have any of the symptoms listed below, or if you have already been investigated and told that your results are 'borderline' or 'within normal limits' but your cycles remain irregular. Early specialist input can shorten the time to diagnosis and treatment, which matters particularly for women whose ovarian reserve may be declining.